Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation.
about
Current Understanding of the Role of Complement in IgA NephropathyMechanisms of Natural Tolerance in the IntestineType V protein secretion pathway: the autotransporter storySimilar proportions of immunoglobulin A1 (IgA1) protease-producing streptococci in initial dental plaque of selectively IgA-deficient and normal individuals.Different effects of whole-cell and acellular vaccines on Bordetella transmission.Relationship of impairment of schistosome 28-kilodalton glutathione S-transferase (GST) activity to expression of immunity to Schistosoma mattheei in calves vaccinated with recombinant Schistosoma bovis 28-kilodalton GSTEvaluation of immunoglobulin A1 (IgA1) protease and IgA1 protease-inhibitory activity in human female genital infection with Neisseria gonorrhoeae.Secretory immunoglobulin A: from mucosal protection to vaccine development.Mannose-containing oligosaccharides of non-specific human secretory immunoglobulin A mediate inhibition of Vibrio cholerae biofilm formation.Inhibitors of complement activity in human breast-milk: a proposed hypothesis of their physiological significanceKilling of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes.Oral microbial ecology and the role of salivary immunoglobulin ARole and significance of the complement system in mucosal immunity: particular reference to the human breast milk complement.Effects of supplemental fructooligosaccharides plus mannanoligosaccharides on immune function and ileal and fecal microbial populations in adult dogs.The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions.Analysis of the immunoglobulin A protease gene of Streptococcus sanguis.Microbiome, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections.Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal diseaseFunctional properties of nonhuman primate antibody to Porphyromonas gingivalis.Prolonged and preferential production of polymeric immunoglobulin A in response to Streptococcus pneumoniae capsular polysaccharides.Systemic and mucosal immune responses in mice orally immunized with avirulent Salmonella typhimurium expressing a cloned Porphyromonas gingivalis hemagglutinin.Increased mucosal production of monomeric IgA1 but no IgA1 protease activity in Helicobacter pylori gastritis.Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies.Tolerance and protection against infection in the genital tract.Role of virulence factors and host cell signaling in the recognition of Helicobacter pylori and the generation of immune responses.Structure and function relationships in IgA.Gate-keeper function of the intestinal epithelium.The effect of age and carbohydrate and protein sources on digestibility, fecal microbiota, fermentation products, fecal IgA, and immunological blood parameters in dogs.Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophreniaImmunity at mucosal surfaces.Intestinal IgA: novel views on its function in the defence of the largest mucosal surface.The effects of inulin supplementation of diets with or without hydrolysed protein sources on digestibility, faecal characteristics, haematology and immunoglobulins in dogs.Heterogeneity of IgG glycosylation in adult periodontal disease.Age-dependent decrease of polymeric Ig receptor expression and IgA elevation in ddY mice: a possible cause of IgA nephropathy.
P2860
Q26852163-AF2193A7-EE43-448F-B038-327FFD015C61Q29031968-3E194022-D4F8-4D89-A820-B8B6CA4EBC52Q33559645-F03C9527-71DD-47F9-997E-F21E8B591152Q33609134-C66AABCE-3624-4C80-8E67-BE09FF35F2DFQ33684401-52BFC352-1C3B-4C00-BA46-698E66BA0892Q33751667-E3BFA785-FC41-4AE8-9DAB-FC19B520C791Q33769074-64F22347-1423-4118-8024-75400766BEE3Q33805948-D6BC1EFB-A3ED-4EA8-855E-6A98429DBF41Q33828704-F59C178F-7CFA-4700-97EE-7113ADA19401Q33855076-DF294887-771C-488C-83EE-1E5876D5416AQ33859127-96CA7147-F48B-41AC-A994-F59FCCF9C3B6Q34009973-370ADE9B-758D-4B04-A5CF-B688E2744784Q34135699-F373C623-291B-4E59-8A82-DD3D31382374Q34162331-7DB560BD-BDC2-4C71-9E5F-3CA3316FF446Q34453640-FB5B06D3-65F6-47B6-B7ED-DEB051E4A987Q35010179-DCCD7B0B-2C94-49A9-A2C0-1E9B012D4E0EQ35019917-30F148CD-09D0-4902-9A1E-1145B12E0832Q35431790-8A57DBD6-2F98-4E3C-889B-FEE4B9A923DCQ35433582-2B92E647-3C1B-477A-B69F-FA5146B34943Q35526521-641662AA-0730-4C10-B580-36B028DF36F2Q35778945-0F9B65A6-45A0-423C-9BB6-88CE760F708AQ35788299-E2F633DC-4C22-4E9A-98AE-9F12CB5D2F40Q35833488-6F9E8484-10A0-47F8-A456-4326F13BCFFCQ37744918-E1F9CE18-CB5F-40AF-8FAF-6907D67C061EQ37781064-5F121C90-6016-4652-8F45-71AFB2297EC0Q37936765-A2E45550-FE2B-428F-84FE-0FECD35C17E5Q38068982-996B6BAB-7DFE-46BD-895C-2A7B6A051E33Q38670512-6F873239-579E-4AC3-8E95-11E9AD0650BAQ38817381-307C88DB-8354-4A33-9D5D-3C015E790458Q38961202-4C6188F5-E48E-46B7-B8A1-8D6696A58CE3Q40706471-CB0CBF02-4BF4-4FD9-8F84-27A060F75803Q41173224-7CEC80E1-7DA0-4928-BD10-C34E704AC93FQ41231842-9C40DE56-865A-4016-BD6E-1B9026E7E4A2Q41846177-5576E1A5-0086-497E-9C99-B3F9C5B174FAQ43340654-B59A7D41-C533-4E6A-8A5A-F2B91A7CC285Q51963760-6048B7A9-3256-4A1F-84E3-67961C60B7F4Q54741636-9ABC2AAE-F73D-44D6-80E4-E9FF75094EA8
P2860
Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Anti-inflammatory activity of ...... ediated complement activation.
@en
type
label
Anti-inflammatory activity of ...... ediated complement activation.
@en
prefLabel
Anti-inflammatory activity of ...... ediated complement activation.
@en
P2860
P356
P1476
Anti-inflammatory activity of ...... ediated complement activation.
@en
P2093
Reinholdt J
Russell MW
P2860
P304
P356
10.1002/EJI.1830191210
P407
P577
1989-12-01T00:00:00Z